Drug intelligence / Profile preview

PRX303

Development stage: Preclinical
Lead developer: Prazer Therapeutics
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

PRX303 is a small molecule drug candidate developed by Prazer Therapeutics for the treatment of Parkinson's disease. It is designed as a proteolysis-targeting chimera (PROTAC) that targets and promotes the degradation of alpha-synuclein protein, a key pathological hallmark in Parkinson's disease. The drug utilizes Prazer Therapeutics' SPiDEM platform and represents a novel approach to reducing toxic alpha-synuclein accumulation in neurodegenerative disorders. As of the latest updates, development remains at the discovery or early research stage, with no clinical trials yet reported beyond preclinical research[1][2].

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on PRX303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRX303.

Explore the full profile